ReviewBioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy2013
Treatment of graft-versus-host disease with naturally occurring T regulatory cells.
Review in BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 39 citations in OpenAlex.
- Safety and efficacy of the therapy with CD4 + CD25highCD127-T regulatory cells: When paediatric patient becomes adult.Diabetes, obesity & metabolism · 2026Article
- Chimeric antigen receptor T cell therapy for autoimmune disease.Nature reviews. Immunology · 2024Review
- Opportunities for Treg cell therapy for the treatment of human disease.Frontiers in immunology · 2023Review
- Cells to the Rescue: Emerging Cell-Based Treatment Approaches for NMOSD and MOGAD.International journal of molecular sciences · 2021Review
- Antigenic Challenge Influences Epigenetic Changes in Antigen-Specific T Regulatory Cells.Frontiers in immunology · 2021Article
- Cyclosporine A but Not Corticosteroids Support Efficacy ofFrontiers in immunology · 2021Article
- Coexpression of FOXP3 and a Helios isoform enhances the effectiveness of human engineered regulatory T cells.Blood advances · 2020Article
- The Future of Regulatory T Cell Therapy: Promises and Challenges of Implementing CAR Technology.Frontiers in immunology · 2020Review
- Successful Regulatory T Cell-Based Therapy Relies on Inhibition of T Cell Effector Function and Enrichment of FOXP3+ Cells in a Humanized Mouse Model of Skin Inflammation.Journal of immunology research · 2020Article
- Transplantation of donor grafts with defined ratio of conventional and regulatory T cells in HLA-matched recipients.JCI insight · 2019Article
- Ways Forward for Tolerance-Inducing Cellular Therapies- an AFACTT Perspective.Frontiers in immunology · 2019Review
- Human LAPTheranostics · 2019Article
- Advance in Targeted Immunotherapy for Graft-Versus-Host Disease.Frontiers in immunology · 2018Review
- DNA Methyltransferase Inhibition Promotes Th1 Polarization in Human CD4Journal of immunology research · 2018Article
- T-cell immunity in myocardial inflammation: pathogenic role and therapeutic manipulation.British journal of pharmacology · 2017Review
- The immunosuppressive effect of the tick protein, Salp15, is long-lasting and persists in a murine model of hematopoietic transplant.Scientific reports · 2017Article
- Cell-Based Therapies with T Regulatory Cells.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2017Review
- Plasmacytoid dendritic cells in allogeneic hematopoietic cell transplantation: benefit or burden?Bone marrow transplantation · 2016Review
- Linezolid Induced Twice Pure Red Cell Aplasia in a Patient with Central Nervous System Infection after Allogeneic Stem Cell Transplantation.Iranian journal of pharmaceutical research : IJPR · 2016Article
- Origin and functions of pro-inflammatory cytokine producing Foxp3+ regulatory T cells.Cytokine · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A significant body of evidence suggests that treatment with naturally occurring CD4(+)CD25(+) T regulatory cells (Tregs) is an appropriate therapy for graft-versus-host disease (GvHD). GvHD is a major complication of bone marrow transplantation in which the transplanted immune system recognizes recipient tissues as a non-self and destroys them. In many cases, this condition significantly deteriorates the quality of life of the affected patients. It is also one of the most important causes of death after bone marrow transplantation. Tregs constitute a population responsible for dominant tolerance to self-tissues in the immune system. These cells prevent autoimmune and allergic reactions and decrease the risk of rejection of allotransplants. For these reasons, Tregs are considered as a cellular drug in GvHD. The results of the first clinical trials with these cells are already available. In this review we present important experimental facts which led to the clinical use of Tregs. We then critically evaluate specific requirements for Treg therapy in GvHD and therapies with Tregs currently under clinical investigation, including our experience and future perspectives on this kind of cellular treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.